Cancer Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Lymphoma
Oral formulation of Fludara approved in Japan
February 27th, 2007
Bayer Schering Pharma AG announced that the oral formulation of Fludara for low-grade non-Hodgkin's Lymphoma and mantle cell lymphoma has received marketing approval in Japan. This new formulation provides a new avenue for simpler and easier outpatient chemotherapy to improve patients' quality of life, as well as that of their families. Bayer Schering Pharma plans to start marketing of Fludara Oral after National Healthcare Insurance price listing. "With the approval of Fludara Oral in Japan, we are right on track to further expand our leadership position in hematological oncology," said Paolo Pucci, head of the Oncology Business Unit at Bayer...
Source: Cancer Weekly (2007-02-27)
|
